VTYX
Ventyx Biosciences, Inc. · Healthcare
14.00
0.00%(+0.00)
Prev. Close14.00
0.00%(+0.00)
Pre-marketLast Updated: — ET
52W L: $0.7852W H: $25.00
$0.00
CHG+0.00 (+0.00%)
H$0.00
L$0.00
VTYX (1h)
Ventyx Biosciences, Inc. · Healthcare
JPMorgan Chase and Co. lifted its position in Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 748,088 shares of the company's stock after acquiring an additional 290,169 shares during the period. JPMorgan Chase
Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) shares saw unusually-high trading volume on Friday. Approximately 16,181,427 shares changed hands during mid-day trading, an increase of 257% from the previous session's volume of 4,538,231 shares.The stock last traded at $13.9850 and had previously closed at $13.97. Analysts Set New Price Targets A number of
Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Analyst Recommendations This is a breakdown of recent
Cibc World Market Inc. reduced its position in Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 39.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,250 shares of the company's stock after selling 99,750 shares during the period. Cibc World Market Inc.
Shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) have earned a consensus recommendation of "Reduce" from the nine analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and eight have issued a hold recommendation on the company. The average 12 month price target among
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences, Inc. (NasdaqGS: VTYX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Ventyx will receive $14.00 in cash for each share of Ventyx that they own. KSF is seeking to determine whether this consideration and the process that led to i.
Gonzales Roy
officer: Senior VP, Finance
5,313 SH @ $14.00
2026-03-04
Gonzales Roy
officer: Senior VP, Finance
37,500 SH @ $2.14
2026-03-04
Gonzales Roy
officer: Senior VP, Finance
70,000 SH @ $33.84
2026-03-04
Gonzales Roy
officer: Senior VP, Finance
12,500 SH @ $4.67
2026-03-04
Gonzales Roy
officer: Senior VP, Finance
35,000 SH @ $2.49
2026-03-04
Subramaniam Somu
director
15,937 SH @ $34.83
2026-03-04
Subramaniam Somu
director
40,000 SH @ $2.25
2026-03-04
Subramaniam Somu
director
3,337,495 SH @ $14.00
2026-03-04